Source: Geerling G, et al. Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment (PERSPECTIVE study). Ophthalmol Ther. 2022.
Delivering sustained corneal surface recovery and symptom relief over 12 months (PERSPECTIVE Study)
Study Architecture
Design
Prospective, multicenter, observational
Population
472 adults (Severe Keratitis + DED)
Duration
12 Months
Comparison
Baseline vs W4, W12, W24, M12
Corneal Fluorescein Staining (CFS) Reduction
Patients demonstrating reduction by Month 12
77.5%
>2 grades reduced (47.5%)
Clinical Sign Reduction
P < 0.0001 vs Baseline
Inflammation Control
P < 0.001 (Conjunctival Erythema)
Tear Film Stability
P < 0.001 (TBUT Increase)
Clinical Recommendation
Integrate CsA 0.1% CE early for patients symptomatic on artificial tears. The PERSPECTIVE study validates efficacy in a real-world setting, confirming that earlier intervention prevents disease progression.
Rapid Onset: Significant improvements by Week 4.
High Tolerability: 83.6% of AEs were mild/moderate.
AbbreviationsQuick
AE, adverse event; AT, artificial tear; CE, cationic emulsion; CFS, corneal fluorescein staining; CsA, cyclosporine A; DED, dry eye disease; FAS, full analysis set; QoL, quality of life; SD, standard deviation; TBUT, tear film breakup time; VA, visual acuity.
Bibliography8
Geerling G, Hamada S, Trocme S, et al. Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment. Ophthalmol Ther. 2022. (DOI: 10.1007/s40123-022-00487-x | link)
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.
Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125–31.
Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678–85.
Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–30.
European Medicines Agency. Ikervis Summary of product characteristics. Last review March 2020. (link)